Comparative Pharmacology
Head-to-head clinical analysis: CANASA versus SFROWASA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANASA versus SFROWASA.
CANASA vs SFROWASA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine (5-aminosalicylic acid) is an anti-inflammatory agent that inhibits prostaglandin and leukotriene synthesis, scavenges reactive oxygen species, and inhibits cytokine production and nuclear factor-kappa B (NF-κB) activation in colonic mucosa.
SFROWASA is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Mesalamine 1000 mg rectally once daily at bedtime, or 500 mg rectally twice daily (morning and evening). Administered as suppository for ulcerative colitis.
5-aminosalicylic acid (mesalamine) 1 g orally 4 times daily for acute treatment; maintenance 500 mg orally 3 times daily.
None Documented
None Documented
Terminal elimination half-life of mesalamine is approximately 0.5-2 hours; however, the N-acetyl metabolite has a half-life of 5-10 hours. Due to the sustained-release formulation, clinical effects persist beyond the plasma half-life.
Terminal elimination half-life: 12-14 hours in healthy adults; prolonged in hepatic impairment (up to 24 hours) or severe renal disease (up to 20 hours).
Renal (approximately 20-30% as unchanged drug and metabolites, primarily N-acetyl-5-aminosalicylic acid); biliary/fecal (the remainder, with extensive enterohepatic circulation).
Renal: 80% as unchanged drug; biliary/fecal: <15% as metabolites; minor hepatic metabolism via CYP3A4.
Category C
Category C
Aminosalicylate
Aminosalicylate